Protein Trans -Splicing as a Means for Viral Vector-Mediated In Vivo Gene Therapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Inteins catalyze protein splicing in a fashion similar to how self-splicing introns catalyze RNA splicing. Splitinteins catalyze precise ligation of two separate polypeptides through trans-splicing in a highly specific manner. Here we report a method of using protein trans-splicing to circumvent the packaging size limit of gene therapy vectors. To demonstrate this method, we chose a large dystrophin gene and an adeno-associated viral (AAV) vector, which has a small packaging size. A highly functional 6.3-kb Becker-form dystrophin cDNA was broken into two pieces and modified by adding appropriate split-intein coding sequences, resulting in splitgenes sufficiently small for packaging in AAV vectors. The two split-genes, after codelivery into target cells, produced two polypeptides that spontaneously trans-spliced to form the expected Becker-form dystrophin protein in cell culture in vitro. Delivering the split-genes by AAV1 vectors into the muscle of a mouse model of Duchenne muscular dystrophy rendered therapeutic gene expression and benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654 · cited 1×
“…and nontoxic vehicle for delivering genes to muscle tissues, as has been demonstrated with a number of muscle genes and reporter genes (Xiao et al ., 1996, 2000; Fisher et al ., 1997; Snyder et al ., 1997; Hartigan-O’Connor and Chamberlain, 2000; Wang et al ., 2000; Watchko et al ., 2002).”
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 2×
“This cDNA was isolated from a Becker muscular dystrophy patient more than 60 years of age with mild symptoms (England et al ., 1990).”
InfluentialTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · cited 1×
“The protein trans-splicing method shows certain unique advantages as well as disadvantages, when compared with other, similar methods such as the dual AAV vectors (Duan et al., 2000; Nakai et al., 2000; Sun et al., 2000; Yan et al., 2000).”
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267 · cited 1×
“The protein trans-splicing method shows certain unique advantages as well as disadvantages, when compared with other, similar methods such as the dual AAV vectors (Duan et al ., 2000; Nakai et al ., 2000; Sun et al ., 2000; Yan et al ., 2000).”
Self-citationDuan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 1×
“Another dual vector method relied on homologous DNA recombination to fuse the split-genes in a target cell (Duan et al ., 2001), but homologous recombination in mammalian cells is notoriously inefficient.”
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2000) · Nature Medicine · doi:10.1038/75080 · Cited by 200 · cited 1×
“The protein trans-splicing method shows certain unique advantages as well as disadvantages, when compared with other, similar methods such as the dual AAV vectors (Duan et al ., 2000; Nakai et al ., 2000; Sun et al ., 2000; Yan et al ., 2000).”
Qiao, C., Li, J., Zhu, T., Draviam, R., Watkins, S., Ye, X., Chen, C., Li, J., & Xiao, X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502137102 · Cited by 92 · cited 1×
“Miniaturized genes have also been constructed by deleting putatively nonessential regions of large genes (Zhang et al., 1998; Wang et al., 2000; Harper et al., 2002; Qiao et al., 2005), but many genes may not tolerate large deletions without losing at least some known or unknown functions.”
Self-citationExpression of Human Factor VIII by Splicing between Dimerized AAV Vectors
Chao, H., Sun, L., Bruce, A., Xiao, X., & Walsh, C. E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0607 · Cited by 75
Self-citation
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
Inteins: nature's gift to protein chemists
Shah, N. H., & Muir, T. W. (2014) · Chem. Sci. · doi:10.1039/c3sc52951g · Cited by 404
Development of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371
“The split-sites of SpCas9 were carefully chosen between Glu573 and Cys574 for the first version (v1) or between Lys637 and Thr638 for the second version (v2), since the N-terminal amino acid of the C-Cas9 in the C-Intein CCas9 fusion should be Cys, Ser or Thr to ensure high splicing efficiency (7,25) (Figure 1a).”
BackgroundMethodTornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Nature's recipe for splitting inteins
Aranko, A. S., Wlodawer, A., & Iwai, H. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu028 · Cited by 116
“…þþþþ N.D. Mills et al. (1998) EN C97 Psp-GDBPol-1 þþ N.D. Southworth et al. (1998) EN C87 PfuRIR1-2 þþþþ N.D. Otomo et al. (1999a) EN C64 SceVMAD206 þþþ 9.4+2.0 1024d Brenzel et al. (2006) EN C51 RmaDnaBD271 þþþþ N.D. Li et al. (2008) EN C50 MtuRecAD285 þþþ N.D. Lew et al. (1998) EN C48…”
InfluentialKoo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104
“Several groups have successfully transferred genes with ORFs larger than 4.5kb, such as a 6.3kb Becker-type human minidystrophin transgene by dual trans-splicing or over-lapping AAV approaches (Ghosh et al. , 2006; Li et al. , 2008; Zhang et al. , 2013).”
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
Therapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Tornabene, P., Trapani, I., Centrulo, M., Marrocco, E., Minopoli, R., Lupo, M., Iodice, C., Gesualdo, C., Simonelli, F., Surace, E. M., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.004 · Cited by 25
Metadata
- Authors
- Li, J., Sun, W., Wang, B., Xiao, X., & Liu, X.-Q.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2008-09
- Volume
- 19
- Issue
- 9
- Pages
- 958-964
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2037965284
- Cited by
- 114
- References
- 9
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.